The_DT
position_NN
of_IN
the_DT
ZEBRA_NN
activation_NN
domain_NN
does_VBZ
not_RB
influence_VB
its_PRP$
biological_JJ
activity_NN
._.

Epstein-Barr_JJ
virus_NN
-LRB-_-LRB-
EBV_NN
-RRB-_-RRB-
is_VBZ
a_DT
human_JJ
herpesvirus_NN
which_WDT
latently_RB
infects_VBZ
B_NN
lymphocytes_NNS
._.

EBV_NN
encodes_VBZ
a_DT
unique_JJ
transcriptional_JJ
activator_NN
,_,
known_VBN
as_IN
ZEBRA_NN
,_,
which_WDT
can_MD
disrupt_VB
viral_JJ
latency_NN
in_IN
B_NN
cells_NNS
and_CC
induce_VB
lytic_JJ
viral_JJ
replication_NN
._.

Furthermore_RB
,_,
ZEBRA_NN
has_VBZ
been_VBN
shown_VBN
to_TO
bind_VB
at_IN
the_DT
EBV_NN
origin_NN
of_IN
lytic_JJ
replication_NN
,_,
and_CC
is_VBZ
necessary_JJ
for_IN
viral_JJ
DNA_NN
replication_NN
to_TO
occur_VB
._.

Previously_RB
we_PRP
demonstrated_VBD
that_IN
heterologous_JJ
activation_NN
domains_NNS
can_MD
fully_RB
substitute_VB
for_IN
the_DT
ZEBRA_NN
activation_NN
domain_NN
._.

Here_RB
we_PRP
extend_VBP
those_DT
results_NNS
by_IN
showing_VBG
that_IN
the_DT
position_NN
of_IN
the_DT
ZEBRA_NN
activation_NN
domain_NN
or_CC
a_DT
heterologous_JJ
replacement_NN
domain_NN
does_VBZ
not_RB
influence_VB
its_PRP$
ability_NN
to_TO
function_VB
in_IN
the_DT
disruption_NN
of_IN
EBV_NN
latency_NN
._.

In_IN
this_DT
study_NN
three_CD
novel_JJ
clones_NNS
were_VBD
constructed_VBN
in_IN
which_WDT
the_DT
ZEBRA_NN
activation_NN
region_NN
was_VBD
repositioned_VBN
to_TO
the_DT
carboxy_JJ
terminus_NN
of_IN
the_DT
protein_NN
._.

These_DT
mutants_NNS
were_VBD
used_VBN
to_TO
demonstrate_VB
that_IN
the_DT
ability_NN
of_IN
ZEBRA_NN
's_POS
wild_JJ
type_NN
domain_NN
to_TO
function_VB
in_IN
the_DT
complex_JJ
biological_JJ
process_NN
of_IN
virus_NN
activation_NN
is_VBZ
not_RB
compromised_VBN
by_IN
altering_VBG
its_PRP$
position_NN
within_IN
the_DT
protein_NN
._.

